MD Anderson study finds that AML patients have high response rate with Vorinostat added to treatment

MD Anderson study finds that AML patients have high response rate with Vorinostat added to treatment   NCI Cancer Center News Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center … Continue reading “MD Anderson study finds that AML patients have high response rate with Vorinostat added to treatment”

MD Anderson study finds that AML patients have high response rate with Vorinostat added to treatment

 

NCI Cancer Center News

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.

Read the full press release from MD Anderson

####

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply